Replies to post #114 on Sunesis Pharmaceuticals (SNSS)

[DAD2]

Conference call on Tuesday

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the company will host a conference call on Tuesday, December 8, 2009 at 2:00 PM EST to discuss the new clinical data from its Phase 2 voreloxin program presented at the 51st Annual American Society of Hematology (ASH) Meeting in New Orleans. Robert K. Stuart, M.D., Professor of Medicine, Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, will join the Sunesis senior management team to review updated data from both its Phase 2 combination study of voreloxin and cytarabine in relapsed or refractory AML patients and the REVEAL-1 study, a Phase 2 dose regimen optimization study of single agent voreloxin in newly diagnosed elderly AML patients who are unlikely to benefit from standard induction chemotherapy.